Clinical Trial Update: A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 trial update of vemurafenib in Chinese participants with BRAF V600 mutation-positive unresectable or metastatic melanoma has completed recruitment wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2016-06-08